Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    150
  • sponsor
    Next Biomedical Co., Ltd.
Updated on 27 April 2022

Summary

The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard treatment.

Description

This study is a prospective study, and the purpose of this study is to investigate and collect clinical information on the safety and efficacy of degradable microsphere for hepatic artery chemoembolization in hepatocellular carcinoma patients. The primary purpose of this study was to evaluate the incidence of postembolism syndrome and liver function impairment after hepatic artery chemoembolization, and the secondary purpose was to evaluate tumor treatment response and hepatic artery damage after 1 month of hepatic artery chemoembolization.

Details
Condition Hepatocellular Carcinoma
Treatment Nexsphere™
Clinical Study IdentifierNCT05072041
SponsorNext Biomedical Co., Ltd.
Last Modified on27 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult patients aged 19 to 79 years
Patient who signed Informed Consent Form
Patients diagnosed with hepatocellular carcinoma by American Association for the Study of Liver Diseases (AASLD) and at least one of the following methods i. Magnetic resonance imaging (MRI) with early augmentation and delayed excretion of at least one solid liver lesion greater than 1 ㎝
ii. Contrast-enhanced computed tomography (CT) with early augmentation and
delayed build-up of at least one solid liver lesion >1 ㎝
iii. Lesions with inconclusive features require histological confirmation
Patients should not be eligible for treatment by amputation or percutaneous resection or liver transplantation at the time of study enrollment
Patients who are not suitable for ablation due to lesion location may be enrolled
ii. Patients with recurrent hepatocellular carcinoma who are not suitable for
amputation or resection may be enrolled
Must be Child-Pugh A or B hepatocellular carcinoma, and must satisfy the following criteria
Tumor lesion size from 1 ㎝ to 10 ㎝ ii. Number of tumors 1-7 iii. Physical activity European Cooperative Oncology Group (ECOG) ≤ 1 without vascular involvement
Patients who can be followed up until the end of the study and whose life expectancy is 6 months or longer

Exclusion Criteria

Patients under the age of 19
Chronic kidney disease (CDK) grade 4 or 5 patients
Current or previous treatment with chemotherapy or radiation therapy or sorafenib or drug release chemoembolization (deTACE) after diagnosis of hepatocellular carcinoma
Pregnant, lactating, pre-menopausal and women not using effective contraceptive methods
Performance state European Cooperative Oncology Group (ECOG) > 1 7. Child-Poo Class C 8. Advanced hepatocellular carcinoma with vascular invasion or extrahepatic metastasis 9. Active Gastrointestinal Bleeding 10. Evidence of irreversible bleeding constitution 11. Encephalopathy that is not medically adequately controlled 12. Presence of ascites that is not medically controlled 13. Contraindications to Magnetic Resonance Imaging or Computed Tomography scan (e.g. metal implants) 14. Allergy to contrast media that cannot be managed by prevention 15. Contraindications to angiography 16. Contraindications to the administration of cisplatin anticancer drugs 17. Contraindications to hepatic artery embolization
Extensive context-to-systemic shunts
hepatofugal portal blood flow
Serum bilirubin > 3.0 ㎎/dL
Serum creatinine > 2.0 ㎎/dL
Other symptoms that your doctor has determined to be exclusive
Irreversible blood clotting disorders 18. Others who are judged to be difficult for the principal investigator or principal investigator to conduct this clinical trial for other reasons
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note